PHOX2B is a suppressor of neuroblastoma metastasis

Osnat Naftali, Shelly Maman, Tsipi Meshel, Orit Sagi-Assif, Ravit Ginat, Isaac P. Witz*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Paired like homeobox 2B (PHOX2B) is a minimal residual disease (MRD) marker of neuroblastoma. The presence of MRD, also referred to as micro-metastases, is a powerful marker of poor prognosis in neuroblastoma. Lung metastasis is considered a terminal event in neuroblastoma. Lung micrometastatic neuroblastoma (MicroNB) cells show high expression levels of PHOX2B and possess a less malignant and metastatic phenotype than lung macro metastatic neuroblastoma (MacroNB) cells, which hardly express PHOX2B. In vitro assays showed that PHOX2B knockdown in MicroNB cells did not affect cell viability; however it decreased the migratory capacity of the MicroNBshPHOX2B cells. An orthotopic inoculation of MicroNB-shPHOX2B cells into the adrenal gland of nude mice resulted in significantly larger primary tumors and a heavier micro-metastatic load in the lungs and bone-marrow, than when control cells were inoculated. PHOX2B expression was found to be regulated by methylation. The PHOX2B promoter in MacroNB cells is significantly more methylated than in MicroNB cells. Demethylation assays using 5-azacytidine demonstrated that methylation can indeed inhibit PHOX2B transcription in MacroNB cells. These pre-clinical data strongly suggest that PHOX2B functions as a suppressor of neuroblastoma progression.

Original languageEnglish
Pages (from-to)10627-10637
Number of pages11
Issue number9
StatePublished - 2016


  • Metastasis
  • Methylation
  • Minimal residual disease
  • Neuroblastoma
  • PHOX2B


Dive into the research topics of 'PHOX2B is a suppressor of neuroblastoma metastasis'. Together they form a unique fingerprint.

Cite this